Memòria 2010 - IISPV

Àmbit estratègic 5. Salut i medi ambient (toxicologia, microbiologia, malalties infeccioses i VIH/sida)ENTITAT FINANÇADORA:Agència de Gestió d’Ajuts Universitaris i deRecercaNÚMERO D’EXPEDIENT:2009 SGR 1061IMPORT CONCEDIT:42.500 €PERÍODE D’EXECUCIÓ:2009-2013PublicacionsCID J, AGUINACO R, SÁNCHEZ R, GARCÍA-PARDO G,LLORENTE A. Neutrophil CD64 expressionas a marker of bacterial infection: a systematicreview and meta-analysis. J Infect.2010; 60:313-9. FI: 3,060. 2n quartil.TREVIÑO A, SORIANO V, GRUPO ESPAÑOL PARA ELESTUDIO DEL VIH-2 Y HTLV (VELOSO S). Currentsituation of human immunodefi ciencyvirus type 2 and human T lymphotropic virusin Spain. Enferm Infecc Microbiol Clin.2010; 28:442-5. FI: 1,434. 4t quartil.TREVIÑO A, GARCÍA J, DE MENDOZA C, BENITO R,AGUILERA A, ORTÍZ DE LEJARAZU R, RAMOSJM, TRIGO M, EIRÓS JM, RODRÍGUEZ-IGLESIASM, TORRES A, CALDERÓN E, HERNANDEZ A,GOMEZ C, MARCAIDA G, SORIANO V; HTLVSPANISH STUDY GROUP (VELOSO S). Prevalenceof HLTV-1/2 infections in Spain: Across-sectional hospital-based survey.AIDS Res Hum Retrov. 2010; 26:861-4.FI: 2,200. 3r quartil.DOMINGO P, TORRES-TORRONTERAS J, POMAR V,GIRALT M, DOMINGO JC, GUTIERREZ MDEL M,GALLEGO-ESCUREDO JM, MATEO MG, CANO-SOLDADO P, FERNANDEZ I, PASTOR-ANGLADAM, VIDAL F, VILLARROYA F, ANDREU A, MARTIR. Uridine metabolism in HIV-1-infectedpatients: effect of infection, of antiretroviraltherapy and of HIV-1/ART-associatedlipodystrophy síndrome. PLoS One. 2010;5:e13896. FI: 4,300. 1r quartil.DOMINGO P, GALLEGO-ESCUREDO JM, DOMINGOJC, GUTIÉRREZ MDEL M, MATEO MG, FERNÁN-DEZ I, VIDAL F, GIRALT M, VILLARROYA F. SerumFGF21 levels are elevated in associationwith lipodystrophy, insulin resistance andbiomarkers of liver injury in HIV-1-infectedpatients. AIDS. 2010; 24:2629-37. FI:4,909. 1r quartil.MARTÍNEZ E, LARROUSSE M, LLIBRE JM, GUTIÉRREZF, SAUMOY M, ANTELA A, KNOBEL H, MURILLASJ, BERENGUER J, PICH J, PÉREZ I, GATELL JM;SPIRAL STUDY GROUP (VIDAL F, PERAIRE J).Substitution of raltegravir for ritonavir-boostedprotease inhibitors in HIV-infectedpatients: the SPIRAL study. AIDS. 2010;24:1697-707. FI: 4,909. 1r quartil.VELOSO S, PERAIRE J, VILADÉS C, LÓPEZ-DUPLAM, ESCOTÉ X, OLONA M, GARCIA-PARDO G,GÓMEZ-BERTOMEU F, SORIANO A, SIRVENT JJ,VIDAL F. Pharmacogenetics of the metabolicdisturbances and atherosclerosis associatedwith antiretroviral therapy in HIVinfectedpatients. Curr Pharm Des. 2010;16:3379-89. FI: 4,414. 1r quartil.THE OPPORTUNISTIC INFECTIONS PROJECT OF THE CO-LLABORATION OF OBSERVATIONAL HIV EPIDEMIO-LOGICLA RESEARCH IN EUROPE (COHERE, VIDALF). It is safe to discontinue primary Pneumocystisjiroveci pneumonia prophylaxisin patients virologically suppressed HIVinfection and a CD4 cell count